Burning Rock Biotech Ltd (BNR) - Net Assets
Based on the latest financial reports, Burning Rock Biotech Ltd (BNR) has net assets worth $535.60 Million USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($820.90 Million) and total liabilities ($285.29 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Burning Rock Biotech Ltd tangible net worth ratio to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $535.60 Million |
| % of Total Assets | 65.25% |
| Annual Growth Rate | 15.55% |
| 5-Year Change | -70.97% |
| 10-Year Change | N/A |
| Growth Volatility | 161.56 |
Burning Rock Biotech Ltd - Net Assets Trend (2017–2025)
This chart illustrates how Burning Rock Biotech Ltd's net assets have evolved over time, based on quarterly financial data. See Burning Rock Biotech Ltd defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Burning Rock Biotech Ltd (2017–2025)
The table below shows the annual net assets of Burning Rock Biotech Ltd from 2017 to 2025. For live valuation and market cap data, see Burning Rock Biotech Ltd (BNR) total market value.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $535.60 Million | -7.79% |
| 2024-12-31 | $580.83 Million | -24.41% |
| 2023-12-31 | $768.41 Million | -33.66% |
| 2022-12-31 | $1.16 Billion | -37.23% |
| 2021-12-31 | $1.85 Billion | -23.78% |
| 2020-12-31 | $2.42 Billion | +371.57% |
| 2019-12-31 | $-891.49 Million | -47.73% |
| 2018-12-31 | $-603.46 Million | -458.17% |
| 2017-12-31 | $168.49 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Burning Rock Biotech Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 387879293400.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $141.09K | 0.03% |
| Other Comprehensive Income | $-162.24 Million | -30.29% |
| Other Components | $4.96 Billion | 925.31% |
| Total Equity | $535.60 Million | 100.00% |
Burning Rock Biotech Ltd Competitors by Market Cap
The table below lists competitors of Burning Rock Biotech Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
BitNine Co. Ltd.
KQ:357880
|
$70.08 Million |
|
Sinkang Industries Co Ltd
TW:2032
|
$70.11 Million |
|
Metro Systems Corporation Public Company Limited
BK:MSC
|
$70.13 Million |
|
Codes Combine Co. Ltd
KQ:047770
|
$70.14 Million |
|
Kilitch Drugs (India) Limited
NSE:KILITCH
|
$70.06 Million |
|
Velan Inc.
TO:VLN
|
$70.06 Million |
|
COMMERCIAL SYN BAGS ORD (BSE)
NSE:COMSYN
|
$70.05 Million |
|
Amoeba SA
PA:ALMIB
|
$70.02 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Burning Rock Biotech Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 580,827,000 to 535,604,846, a change of -45,222,154 (-7.8%).
- Net loss of 55,346,000 reduced equity.
- Other comprehensive income decreased equity by 4,192,242.
- Other factors increased equity by 14,316,088.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-55.35 Million | -10.33% |
| Other Comprehensive Income | $-4.19 Million | -0.78% |
| Other Changes | $14.32 Million | +2.67% |
| Total Change | $- | -7.79% |
Book Value vs Market Value Analysis
This analysis compares Burning Rock Biotech Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.02x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | $93.14 | $7.95 | x |
| 2018-12-31 | $-269.66 | $7.95 | x |
| 2019-12-31 | $-379.62 | $7.95 | x |
| 2020-12-31 | $352.74 | $7.95 | x |
| 2021-12-31 | $177.08 | $7.95 | x |
| 2022-12-31 | $111.48 | $7.95 | x |
| 2023-12-31 | $75.04 | $7.95 | x |
| 2024-12-31 | $56.43 | $7.95 | x |
| 2025-12-31 | $496.62 | $7.95 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Burning Rock Biotech Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -10.33%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -10.26%
- • Asset Turnover: 0.66x
- • Equity Multiplier: 1.53x
- Recent ROE (-10.33%) is above the historical average (-41.87%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2017 | -77.91% | -118.09% | 0.28x | 2.38x | $-148.12 Million |
| 2018 | 0.00% | -84.98% | 0.56x | 0.00x | $-117.15 Million |
| 2019 | 0.00% | -44.10% | 0.45x | 0.00x | $-79.19 Million |
| 2020 | -16.82% | -94.73% | 0.16x | 1.10x | $-649.34 Million |
| 2021 | -43.17% | -156.87% | 0.22x | 1.23x | $-981.23 Million |
| 2022 | -83.85% | -172.44% | 0.35x | 1.37x | $-1.09 Billion |
| 2023 | -85.07% | -121.63% | 0.52x | 1.35x | $-730.53 Million |
| 2024 | -59.68% | -67.20% | 0.58x | 1.52x | $-404.71 Million |
| 2025 | -10.33% | -10.26% | 0.66x | 1.53x | $-108.91 Million |
Industry Comparison
This section compares Burning Rock Biotech Ltd's net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $474,621,008
- Average return on equity (ROE) among peers: -198.25%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Burning Rock Biotech Ltd (BNR) | $535.60 Million | -77.91% | 0.53x | $70.07 Million |
| Agilent Technologies Inc (A) | $4.16 Billion | 9.64% | 0.80x | $38.36 Billion |
| Advanced Biomed Inc. Common Stock (ADVB) | $3.48 Million | -2.92% | 0.87x | $6.13 Million |
| Applied DNA Sciences Inc (APDN) | $12.57 Million | -94.54% | 0.24x | $3.99 Million |
| Biodesix Inc (BDSX) | $4.58 Million | -1138.56% | 20.64x | $79.44 Million |
| bioAffinity Technologies, Inc. (BIAF) | $7.28 Million | -204.87% | 0.51x | $3.78 Million |
| Biocept Inc. (BIOCQ) | $37.48 Million | -7.53% | 0.61x | $525.00 |
| BillionToOne, Inc. Class A Common Stock (BLLN) | $30.47 Million | -271.32% | 5.29x | $4.57 Billion |
| CareDx Inc (CDNA) | $-5.95 Million | 0.00% | 0.00x | $1.13 Billion |
| Check Cap Ltd (CHEK) | $23.69 Million | -74.17% | 0.06x | $9.42 Million |
About Burning Rock Biotech Ltd
Burning Rock Biotech Limited develops and sells cancer therapy selection tests in the People's Republic of China and the United States. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company offers next-generation sequencing (NGS)-based tissue, liquid biopsy cancer therapy selection, and prognosis prediction test… Read more